Deutsche Bank Sticks to Its Buy Rating for 3i Group plc (III)
Confident Investing Starts Here:
Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Johnson covers the Financial sector, focusing on stocks such as Saga plc, Hannover Rueck, and Munich Reinsurance. According to TipRanks, Johnson has an average return of 16.3% and an 89.47% success rate on recommended stocks.
Currently, the analyst consensus on 3i Group plc is a Moderate Buy with an average price target of p4,490.83, a 7.93% upside from current levels. In a report released yesterday, Citi also maintained a Buy rating on the stock with a £50.00 price target.
III market cap is currently £40.17B and has a P/E ratio of 7.97.
Based on the recent corporate insider activity of 106 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of III in relation to earlier this year.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
NBC News
5 hours ago
- NBC News
Trump gives drugmakers 60 days to slash prescription drug prices
President Donald Trump sent letters to more than a dozen major drugmakers Thursday demanding that they lower the cost of prescription drugs in the U.S. within 60 days. In the letters — which Trump published on his social media platform Truth Social — the drugmakers were told to offer the 'full portfolio' of their existing medications to Medicaid patients at the same prices paid abroad, also known as the 'most favored nation' rule. He also told drugmakers to 'guarantee' that patients on Medicare, Medicaid and private insurance get the same lower prices that are paid abroad for all newly approved drugs 'both upon launch and moving forward.' He also demanded that drugmakers return any additional revenues earned abroad to U.S. taxpayers, and create a 'direct to consumer' option for certain medications that would also be offered at lower prices. 'Make no mistake: a collaborative effort towards achieving global pricing parity would be the most effective path for companies, the government, and American patients,' Trump wrote in the letters. 'But if you refuse to step up, we will deploy every tool in our arsenal to protect American families from continued abusive drug pricing practices.' It's unclear, experts say, whether Trump has the authority to force drugmakers to lower the cost of their prescription drugs without the help of Congress. What's more, any attempt to do so is likely to be met with fierce pushback from the drug industry. 'It may take more than a tough letter from the President to motivate the pharmaceutical industry to drop their prices,' said Tricia Neuman, executive director of the program on Medicare policy at KFF, a nonpartisan health policy research group. 'The voluntary approach hasn't worked so far to drive down drug prices,' she added. 'Drug prices tend to go down when compelled by law or in response to competition.' Trump has repeatedly complained — during both terms — that people in the U.S. pay far more for prescription drugs than people in other countries. Indeed, prescription drug prices in the United States are notoriously high — up to 10 times more than in other nations of similar size and wealth, according to the Rand Corp., a public policy think tank. More than 3 in 4 adults in the U.S. say the cost of medications is unaffordable, according to a poll from KFF. In May, Trump signed an executive order instructing federal health officials to renew an effort to implement the 'most favored nation' rule — a strategy he pursued unsuccessfully during his first term. The 17 letters were sent Thursday to major drugmakers such as Eli Lilly, GSK, Pfizer, Merck, Johnson & Johnson, Amgen, Novo Nordisk and Novartis. NBC News has reached out to all 17 companies for comment. A spokesperson for Novo Nordisk said the company 'remains focused on improving patient access and affordability, and we will continue to work to find solutions that help people access the medication they need.' A spokesperson for Johnson & Johnson said the company was still reviewing the letter, and referred NBC News to the pharmaceutical industry's top lobbying group, PhRMA, for comment. PhRMA did not immediately respond to a request for comment. The Trump administration does have another tool at its disposal to lower the cost of prescription drugs: Medicare drug pricing negotiations. Signed into law by President Joe Biden through the Inflation Reduction Act, the provision allows Medicare to negotiate prices on the costliest medications. The first round of negotiations is estimated to save Medicare $6 billion in 2026, when the prices are expected to go into effect.
CNBC
7 hours ago
- CNBC
How wealthy yacht buyers plan to avoid the European tariffs
American boat buyers and European shipyards are scrambling to assess the damage from the proposed U.S. 15% tariffs on European-made goods. With many of the world's recreational boats and yachts made in Europe, and most of the biggest buyers in the U.S., industry experts are bracing for the fallout from President Donald Trump's Monday tariff announcement. The European Boating Industry issued a statement this week saying, "The U.S. is the most important export market for the recreational boating industry in Europe. The 15% tariff rate presents serious challenges for businesses in Europe." Granted, most Americans can who buy a $10 million or $100 million yacht can likely afford another 15% tax. Yet brokers said the cost equation for many buyers will change with the tariffs. "I don't know any stupid rich people," said Kevin Merrigan, chairman of Northrop & Johnson, the yacht brokerage firm. "What matters to them matters. If they hear they're going to have to spend another 15%, it has an impact." The Inside Wealth newsletter by Robert Frank is your weekly guide to high-net-worth investors and the industries that serve them. Subscribe here to get access today. Most boat contracts require the builder to pay duties. Yet attorneys said the new tariffs aren't likely to fall under existing duties, and the buyers will likely have to pay a portion, if not the majority. Brokers said many buyers who purchased their yachts a year or two ago — since a specialized build can take three years from start to finish —are negotiating now with the shipyards. In the meantime, brokers said the wealthy will do what they typically do when faced with a new tax — find a way around it. The most common strategy will likely be to register the boat in another country, known as "foreign flagging." An American buyer can register their yacht in one of several countries that have agreements with the U.S. The most common are the Cayman Islands, the Marshall Islands, Malta and Jamaica, brokers said. By registering the yacht abroad, the owner can enter the U.S. as a visiting vessel and therefore avoid the tariff. There are restrictions and rules, and special cruising permits are required. And it can cost $5,000 to over $20,000 to register in another country. But the savings on a multimillion-dollar yacht are substantial. "If it's never technically imported and it never crosses the customs border line, the tariff doesn't apply," said Michael Moore, a maritime attorney with Moore & Co. Registering in another country usually only makes financial and logistical sense for larger yachts, while smaller boats (say, those under 45 feet) will still likely end up paying the tariff. In that sense, the new tariff regime will create a new class of have-yachts and have-superyachts, with the super-yachters best equipped to escape the 15% tax. Brokers said the tariffs could increase demand for U.S. yacht makers like Westport, Trinity or Burger Boat Company. And with demand for preowned yachts in a slump after a post-Covid surge, many hope sales and prices for preowned yachts already registered in the U.S. will strengthen. "That's my hope," Merrigan said. "That's what we're all hoping."
Yahoo
10 hours ago
- Yahoo
‘The Upside Is Enormous': 2 Quantum Computing Stocks Rosenblatt Is Pounding the Table On
Most historians date the start of the Industrial Revolution to around 1770. Almost 150 years later, in 1913, Henry Ford introduced the assembly line to the factory floor, and some 75 years after that, the widespread use of PCs and networking brought us the internet and digital age. And now we're looking at the advent of quantum computing, which promises to bring dramatically expanded computational power. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Right now, we're on the cusp of the transition between traditional computing and quantum computing. Quantum computers make use of the principles of quantum mechanics and subatomic superpositioning to tackle far more complex problems than traditional digital machines, and to do so far more quickly. According to McKinsey, the addressable market for them is expected to reach as high as $30 billion or more within just 10 years. Add in quantum-based communications and sensing technologies, and the market for quantum tech may hit as high as $97 billion by 2035. One thing is certain: that kind of growth is sure to attract investors. Covering the quantum sector for Rosenblatt, analyst Kevin Garrigan noted: 'For investors, quantum computing represents a long-duration, high-growth opportunity, with near-term commercialization through hybrid quantum-classical solutions in optimization and simulation. While widespread fault-tolerant systems remain a decade away, the strategic upside from quantum's potential to disrupt industries such as pharmaceuticals, advanced materials, financial modeling, and cybersecurity is enormous.' Garrigan has turned that bullish outlook into action, pounding the table on two quantum computing stocks that investors should buy into. And he's not alone, the TipRanks database shows that Wall Street analysts are just as enthusiastic, assigning both names a Strong Buy consensus rating. IonQ (IONQ) We'll start with IonQ, a tech company founded 10 years ago and based in College Park, Maryland. This is a prime location for a cutting-edge tech firm; it is just a few miles from Washington, DC, and it is home to the University of Maryland, giving the company easy access to sources of government and academic support. IonQ is developing trapped ion quantum computing, a method that makes use of electromagnetic fields to trap and hold ions, electrically charged atomic particles, and to make use of their stable electric states to store qubit information, the basic data storage of quantum computing. In effect, IonQ is using the electromagnetic potential inherent in atoms to tap into the properties of the subatomic quantum particles from which they are built. It's an approach that the company describes as 'naturally quantum,' and it is proving highly amenable to storing the qubit data that quantum computers use. Following this path, IonQ has brought its trapped ion approach to fruition in the form of several commercially available quantum computers. The 25-qubit Aria is the company's flagship system, while Forte, IonQ's second system to hit the commercial market, brought an expanded capacity of 36 qubits. IonQ scored a $22 million sale of the Forte Enterprise system during the first quarter of this year, with Chattanooga's EPB as the customer. More recently, IonQ entered into a strategic collaboration with Australia's Emergence Quantum, giving the Maryland firm a foot in the Asia-Pacific arena. IonQ is not standing still, and is working on a new system, Tempo, to bring higher-capacity quantum computers to the commercial market. Tempo is planned and designed as a faster and more useful quantum computer system, with a capacity of at least 64 qubits. We won't see IonQ's 2Q25 results until August 6, but for now we can look back at the company's Q1 report to get a feel for where IonQ stands. In the first quarter of this year, IonQ reported $7.57 million in revenue, flat year-over-year and edging over the forecast by some $56,000. The company reported a quarterly net loss of 14 cents per share, which was 15 cents better than had been expected. At the end of the quarter, IonQ had cash and liquid assets totaling $697.1 million. For Garrigan, in his coverage of the stock, the starting point is IonQ's solid position at the leading edge of the computing world's future. The analyst writes, 'We believe IonQ provides an attractive way to gain exposure to the quantum computing market, a market that we see as the next era of computing. It is our view that the quantum computing market is setup to be a multiple winner market and not a winner takes all market. We have a high level of confidence that IonQ is well positioned to take its place among the winners, and unlike some early stage competitors, IonQ will be exiting 2025 with annualized revenues in excess of $100M, nearly doubling in 2026, and could well be on track for $1B in revenue over the next few years. We believe executing on the product roadmap, developing a quantum ecosystem to capture value in the nascent quantum networking, and increasing partnerships/system sales will drive stock price appreciation.' The analyst goes on to rate IONQ shares as a Buy, and his $70 price target points toward a one-year gain of 73%. (To watch Garrigan's track record, click here) The 7 recent analyst reviews of IonQ include 6 Buys to 1 Hold, for a Strong Buy consensus rating. The stock has a current trading price of $40.53 and its $47.50 average price target suggests that it will appreciate by 17% in the year ahead. (See IONQ stock forecast) D-Wave Quantum (QBTS) The next quantum stock we'll look at is D-Wave, one of the leading companies in the quantum computing sector. D-Wave, whose Palo Alto headquarters are in the heart of Silicon Valley, has been in business since 1999, developing quantum computing from both the hardware and software sides. More importantly, the company is also working on cloud services and app development tools – the very tools and services that will be needed to fully integrate quantum computing into the structure of today's digital world. D-Wave is one of the early entrants into the quantum computing world, and boasts that it was the first company to bring working quantum computers to the market. Currently, D-Wave has several quantum systems available, through the cloud or through 'on-premises' installations. The company claims that its quantum systems have achieved 99.9% availability, an important reliability milestone. Looking ahead, D-Wave has recently released its latest quantum computing system, the advanced Advantage2. This is an annealing quantum computer, designed to optimize problem-solving by locating the lowest energy state of a quantum system. This lower-power approach brings advantages in efficiency and cost of operations, while maintaining the high speed and capabilities inherent in quantum computing. Advantage2 is a sixth-generation quantum computer, and has proven that it can solve complex problems that are far beyond the abilities of even the best 'classical' supercomputers. The system is built to commercial-grade standards, and is intended to meet the needs of real-world customers, such as AI providers. From an investor's perspective, one of D-Wave's biggest advantages is the experience that the company has gained as the leader in bringing quantum computing into real-world use. The company has already dealt with such problems as system optimization, cloud compatibility and networking, and software development to match quantum's capabilities. All of this gives D-Wave a solid foundation, and the company has built itself into a $5.7 billion leader. D-Wave employs experts in physics, cloud infrastructure, and even processor chip manufacturing, and has protected its intellectual property with more than 250 US patents. On the financial side, D-Wave saw record-level revenue in 1Q25, with a top line of $15 million. This was up 507% year-over-year and beat expectations by $4.5 million. At the bottom line, D-Wave's earnings came to a loss of 2 cents per share, a figure that was 3 cents per share better than had been anticipated. D-Wave has deep pockets, and closed out Q1 with a cash balance of $304.3 million on hand. When we check in again with Rosenblatt's Garrigan, we find the analyst upbeat on D-Wave, seeing plenty of opportunities for the firm over the coming years. He writes, 'We believe D-Wave offers a differentiated way to gain exposure to the rapidly growing quantum computing market. It is our view that quantum annealing, a subsector of quantum computing, offers advantages over both classical computing and gate-based quantum systems for optimization workloads. We have a high level of confidence that D-Wave will capture significant market share in the quantum annealing market leading to D-Wave revenues growing at a +66% CAGR from 2025-2030. We believe continued demonstration of quantum supremacy, growing the commercial customer base, and executing on the dual-track product road map will drive stock price appreciation in the long-term.' Once again, Garrigan rates an upwardly mobile quantum computing stock as a Buy, backing that with a $30 price target implying a one-year upside potential of 70%. This is another quantum stock that has earned a Strong Buy consensus rating, this one based on 9 unanimously positive analyst reviews. The shares are priced at $17.67 and their $19.50 average target price suggests an upside of 10% on the one-year horizon. (See QBTS stock forecast) To find good ideas for stocks trading at attractive valuations, visit TipRanks' Best Stocks to Buy, a tool that unites all of TipRanks' equity insights. Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment. Disclaimer & DisclosureReport an Issue
